Soleno Therapeutics (SLNO) Capital Expenditures (2013 - 2026)

Soleno Therapeutics (SLNO) has 12 years of Capital Expenditures data on file, last reported at $40000.0 in Q1 2026.

• Capital Expenditures for Q1 2026 came in at $40000.0, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $113000.0 (down 45.41% YoY), and the FY2025 annual result was $73000.0, down 66.51% from the prior year.
• Capital Expenditures fell to $40000.0 in Q1 2026 per SLNO's latest filing, from $58000.0 in the prior quarter.
• Over five years, Capital Expenditures peaked at $191000.0 in Q3 2024 and troughed at $1000.0 in Q3 2025.
• A 4-year average of $37444.4 and a median of $11000.0 in 2024 frame the typical range for Capital Expenditures.
• On a YoY basis, Capital Expenditures climbed as much as 625.0% in 2025 and fell as far as 99.48% in 2025.
• A 4-year view of Capital Expenditures shows it stood at $6000.0 in 2022, then soared by 33.33% to $8000.0 in 2024, then surged by 625.0% to $58000.0 in 2025, then plunged by 31.03% to $40000.0 in 2026.
• Business Quant data shows SLNO's Capital Expenditures at $40000.0 in Q1 2026, $58000.0 in Q4 2025, and $1000.0 in Q3 2025.